Evidence map›Paper›PMID 38990731›Full record

ArticleCancer research2024

Hypoxic Memory Mediates Prolonged Tumor-Intrinsic Type I Interferon Suppression to Promote Breast Cancer Progression.

Oihana Iriondo, Desirea Mecenas, Yilin Li, Christopher R Chin, Amal Thomas, Aidan Moriarty, Rebecca Marker, Yiru J Wang, Haley Hendrick, Yonatan Amzaleg and 11 more

Abstract read
In one paragraph

Article in Cancer research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors.

Oihana IriondoDepartment of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California.ORCID 0000-0002-7464-5026
Desirea Mecenas *Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California.ORCID 0000-0002-5038-313X
Yilin Li *Department of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California.ORCID 0000-0003-2610-7730
Christopher R ChinDepartment of Physiology and Biophysics, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-2140-3197
Amal ThomasDepartment of Molecular and Computational Biology, USC Dana and David Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, California.ORCID 0000-0003-4494-4487
Aidan MoriartyDepartment of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California.ORCID 0000-0002-9502-937X
Rebecca MarkerDepartment of Pharmacology, University of Maryland School of Medicine, Baltimore, Maryland.ORCID 0009-0007-5018-5815
Yiru J WangDepartment of Pharmacology, University of Maryland School of Medicine, Baltimore, Maryland.ORCID 0009-0009-1040-3229
Haley HendrickDepartment of Pharmacology, University of Maryland School of Medicine, Baltimore, Maryland.ORCID 0009-0005-7534-5454
Yonatan AmzalegDepartment of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California.ORCID 0000-0002-8576-9702
Veronica OrtizDepartment of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California.ORCID 0000-0002-6928-8458
Matthew MacKayDepartment of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California.ORCID 0000-0002-1848-0829
Amber DickersonDepartment of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California.ORCID 0000-0003-0411-5342
Grace LeeDepartment of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California.ORCID 0009-0002-6370-4358
Sevana HarotoonianDepartment of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California.ORCID 0000-0001-6813-4185
Bérénice A BenayounUSC Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, Los Angeles, California.ORCID 0000-0002-7401-4777
Andrew SmithDepartment of Molecular and Computational Biology, USC Dana and David Dornsife College of Letters, Arts and Sciences, University of Southern California, Los Angeles, California.ORCID 0000-0002-3337-1970
Christopher E MasonDepartment of Physiology and Biophysics, Weill Cornell Medicine, New York, New York.ORCID 0000-0002-1850-1642
Evanthia T Roussos TorresUSC Norris Comprehensive Cancer Center, Keck School of Medicine of the University of Southern California, Los Angeles, California.ORCID 0000-0002-0740-5102
Remi KlotzDepartment of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California.ORCID 0000-0003-2100-0635
Min YuDepartment of Stem Cell Biology and Regenerative Medicine, Keck School of Medicine of the University of Southern California, Los Angeles, California.ORCID 0000-0002-3969-8720

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI William Dean Wallace · 1985 to 2026
$181.4M
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTERSUPPORT GRANTP30CA134274 · NCI · UNIVERSITY OF MARYLAND BALTIMORE · PI Vu H. Duong · 2008 to 2026
$51.0M
DOCTORAL AND POST-DOCTORAL TRAINING IN CRANIOFACIAL BIOLOGYT90DE021982 · NIDCR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI PAINE, MICHAEL LANSDELL · 2011 to 2025
$6.2M
Developing Individualized Medicine Targeting Metastatic Breast Cancer Stem CellsDP2CA206653 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YU, MIN · 2015 to 2019
$2.6M
Center for Cancer Research (CCR) DP2CA206653National Institute of Dental and Craniofacial Research (NIDCR) T90DE021982NCI NIH HHS DP2 CA206653NCI NIH HHS P30 CA014089NCI NIH HHS P30 CA134274NIDCR NIH HHS T90 DE021982Pew Charitable Trusts (PCT) Pew-Stewart Scholar for Cancer ResearchThe Broad foundataion The Broad Fellowshipthe Maryland Department of Heath's Cigarette Restitution Fund Program CH-649-CRFthe Richard Merkin Foundation Richard Merkin ScholarThe Stop Cancer Foundattion Career Development AwardU.S. Department of Defense (DOD) W81XWH-20-1-0092
6 · The paper itself

Abstract

Hypoxia is a common feature of many solid tumors due to aberrant proliferation and angiogenesis that is associated with tumor progression and metastasis. Most of the well-known hypoxia effects are mediated through hypoxia-inducible factors (HIF). Identification of the long-lasting effects of hypoxia beyond the immediate HIF-induced alterations could provide a better understanding of hypoxia-driven metastasis and potential strategies to circumvent it. Here, we uncovered a hypoxia-induced mechanism that exerts a prolonged effect to promote metastasis. In breast cancer patient-derived circulating tumor cell lines and common breast cancer cell lines, hypoxia downregulated tumor-intrinsic type I IFN signaling and its downstream antigen presentation (AP) machinery in luminal breast cancer cells, via both HIF-dependent and HIF-independent mechanisms. Hypoxia induced durable IFN/AP suppression in certain cell types that was sustained after returning to normoxic conditions, presenting a "hypoxic memory" phenotype. Hypoxic memory of IFN/AP downregulation was established by specific hypoxic priming, and cells with hypoxic memory had an enhanced ability for tumorigenesis and metastasis. Overexpression of IRF3 enhanced IFN signaling and reduced tumor growth in normoxic, but not hypoxic, conditions. The histone deacetylase inhibitor entinostat upregulated IFN targets and erased the hypoxic memory. These results point to a mechanism by which hypoxia facilitates tumor progression through a long-lasting memory that provides advantages for circulating tumor cells during the metastatic cascade. Significance: Long-term cellular memory of hypoxia leads to sustained suppression of tumor-intrinsic type I IFN signaling and the antigen presentation pathway that facilitates tumorigenesis and metastasis. See related commentary by Purdy and Ford, p. 3125.

Indexed as

Breast NeoplasmsDisease ProgressionInterferon Type IAnimalsAntigen PresentationCell Line, TumorFemaleHumansInterferon Regulatory Factor-3MiceSignal TransductionInterferon Regulatory Factor-3Interferon Type IIRF3 protein, human

Identifiers

PMID38990731
PMCPMC11444891

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.